Vaidya Sane Ayurved Laboratories Ltd (MADHAVBAUG) is currently trading at 141.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Vaidya Sane Ayurved Laboratories Limited is an evidence-focused Ayurvedic healthcare provider operating a network of clinics and hospitals and manufacturing Ayurveda products, combining in-house R&D, franchising and hospital care to treat chronic lifestyle diseases such as cardiac disorders, diabetes, hypertension and obesity across multiple Indian states and international franchise initiatives. Management has shifted strategically from low-ticket preventive wellness to higher-value disease-reversal programs with typical annual patient billing of Rs.50,000–60,000, aiming to improve unit economics; this pivot supports higher ARPU, stronger clinical outcomes and a planned shift toward a roughly 50:50 clinic-to-hospital revenue mix over the medium term. The company reported FY'26 revenue of Rs.106.91 crore (up 18.9% YoY) with EBITDA excluding other income of Rs.15.42 crore and PAT of Rs.8.99 crore, while guiding FY'27 revenue of Rs.170–180 crore and FY'28 enterprise targets of Rs.250–300 crore alongside an EBITDA margin objective above 20%, signalling an ambitious near-term scaling plan. Operational priorities include rapid hospital bed expansion (from ~134 beds to 250–300 within ~12–15 months), an asset-light franchise model adding 30–40 clinics next year, an investment in digital patient engagement through MIB PULSE and Power MAP analytics, and vertical integration via in-house manufacturing subsidiaries to drive margin improvement and supply security.

Over the past 52 weeks, Vaidya Sane Ayurved Laboratories Ltd has traded between a low of ₹130.05 and a high of ₹335.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Vaidya Sane Ayurved Laboratories Ltd has a market capitalization of approximately 148.24. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Vaidya Sane Ayurved Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 37.62 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 148.24 Cr, Vaidya Sane Ayurved Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Vaidya Sane Ayurved Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Vaidya Sane Ayurved Laboratories Ltd is 37.62. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Madhavbaug said it had inadvertently uploaded incorrect details in its earlier filing. The November 5, 2026 submission replaced that disclosure with a corrected consolidated schedule for the half year ended September 30, 2026. The company did not identify the specific error or quantify the difference.

Madhavbaug’s total expenses rose to Rs 60.79 crore from Rs 44.43 crore, exceeding total income of Rs 60.61 crore. Other expenses increased by Rs 11.23 crore, while employee benefits expense increased by Rs 3.10 crore. The result was a Rs 21.80 lakh consolidated loss after a Rs 4.84 crore profit a year earlier.

Vaidya Sane Ayurved reported total income of ₹53.66 crore for the half year ended March 2026. Net sales turnover was ₹52.44 crore and other income was ₹1.22 crore.